Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 8/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2160469 | 0.89 | MAOB (0.33) | MAOBMAPK1KMT2AALDH1A1 | |
| SCHEMBL12935550 | 0.89 | NPC1 (0.33) | KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL2146827 | 0.88 | HSD11B1 (0.34) | HSD11B1MAOBMAPK1KMT2AMAPT | |
| SCHEMBL2158214 | 0.86 | ALDH1A1 (0.36) | MAOBMAPK1KMT2AMAPTLMNA | |
| SCHEMBL2147119 | 0.86 | ALDH1A1 (0.36) | MAOBMAPK1KMT2AMAPTLMNA | |
| SCHEMBL2148983 | 0.86 | MAOB (0.31) | MAOBMAPK1KMT2AALDH1A1 | |
| SCHEMBL2146843 | 0.82 | KMT2A (0.48) | MAOBMAPK1KMT2AMAPTALDH1A1 | |
| SCHEMBL22738298 | 0.81 | MAOB (0.34) | MAOBMAPK1KMT2AMAPTALDH1A1 | |
| SCHEMBL1503232 | 0.80 | CCNA2 (0.36) | MAOBMAPK1KMT2AMAPTLMNA | |
| SCHEMBL2147314 | 0.79 | ALDH1A1 (0.41) | MAOBMAPK1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664248-B2 | Derivatives of pyridoxine for inhibiting HIV integrase | TAIMED BIOLOGICS, INC. (TW) | 2014-03-04 | — | — | US | disclosed |
| US-20120329827-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | AMBRILIA BIOPHARMA, INC. (CA) | 2012-12-27 | — | — | US | disclosed |
| EP-2526091-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | TaiMed Biologics, Inc. (TW) | 2012-11-28 | — | — | EP | disclosed |
| US-8283366-B2 | Derivatives of pyridoxine for inhibiting HIV integrase | AMBRILIA BIOPHARMA, INC. (CA) | 2012-10-09 | — | — | US | disclosed |
| US-20110184028-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | TAIMED BIOLOGICS, INC. (TW) | 2011-07-28 | — | — | US | disclosed |
| WO-2011088549-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | AMBRILIA BIOPHARMA INC. (CA) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184028-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | PNPO, IMPDH1, DPYD | HSD11B1 1163/4885MAOB 141/4885MAPK1 1297/4885 |
| US-20120329827-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | PNPO, IMPDH1, DPYD | HSD11B1 1163/4885MAOB 141/4885MAPK1 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.